Nicotinic Acid

Clinical Lipidology: A Companion to Braunwald's Heart Disease Expert Consult: Online and Print

Volumn , Issue , 2008, Pages 298-314

  Brown, B Greg ^a   Canner, Paul L ^b   McGovern, Mark E ^c   Guyton, John R ^d   Carlson, Lars A ^e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

^c Duke University Medical Center ^*  (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84898697644     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141605469-650029-9     Document Type: Chapter

References (131)

1. Carlson LA Nicotinic acid: The broad spectrum drug A 50 th anniversary review J Intern Med 2005, 258:94-114
2. Altschul R, Hoffer A, Stephen JD Influence of nicotinic acid on serum cholesterol in man Arch Biochem 1955, 54:558-559
3. Anitschokov N Experimental arteriosclerosis in animals Arteriosclerosis: A Survey of the Problem 1933, 271-322 Macmillan, New York EV Cowdry (Ed)
4. Parsons WB, Flinn JH Reduction of serum cholesterol levels and beta-lipoprotein cholesterol levels by nicotinic acid Arch Intern Med 1959, 103:783-790
5. Carlson LA, Oro L The effect of nicotinic acid on the plasma free fatty acids Acta Med Scand 1962, 172:641-645
6. Carlson LA Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro Acta Med Scand 1963, 173:719-722
7. Carlson LA, Havel RJ, Ekelund LG, Holmgren A Effect of nicotinic acid on the turnover rate and oxidation of the free fatty acids in man during exercise Metabolism 1963, 12:837-845
8. Carlson LA, Lassers BW, Wahlqvist ML, Kaijser L The relationship in man between plasma free fatty acids and myocardial metabolism of carbohydrate substrate Cardiology 1972, 57:51-54
9. Havel RJ, Carlson LA, Eckelund LG, Holmgren A Studies on the relation between mobilization of free fatty acids and energy metabolism in man: Effects of norepinepherine and nicotinic acid Metabolism 1964, 13:1402-1412
10. Gordon RS, Cherkes A Unesterified fatty acids in human blood plasma J Clin Invest 1956, 35:206-212
11. Laurell S Recycling of intravenously injected palmitic acid-1-C 14 as esterified fatty acid in the plasma of rats, and turnover rate of plasma triglycerides Acta Physiol Scand 1959, 47:218-223
12. Carlson LA Studies on the incorporation of injected palmitic acid-1-C14 into liver and plasma lipids in man Acta Soc Med Ups 1960, 65:85-89
13. Havel RJ Conversion of plasma free fatty acids into triglycerides of plasma lipoprotein fractions in man Metab Clin Exp 1961, 10:1031-1036
14. Benyo Z, Gille A, Kero J, et al GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing J Clin Invest 2005, 115:3634-3640
15. Pike NB Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid J Clin Invest 2005, 115:3400-3403
16. Tunaru S, Kero J, Schaub A, et al PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect Nat Med 2003, 9:352-355
17. Taggart AK, Kero J, Gan X, et al (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G J Biol Chem 2005, 280:26649-26652
18. Carlson LA, Hanngren A Initial distribution in mice of 3H-labelled nicotinic acid studied by autoradiography Life Sci 1964, 3:867-871
19. Kaijser L, Eklund B, Olsson AG, et al Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man Med Biol 1979, 57:114-117 773-782
20. Morrow JD, Parsons WG, Roberts LJ, et al Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid Prostaglandins 1989, 38:263-274
21. Carlson LA, Ostman J Plasma beta-hydroxybutyric acid response to nicotinic acid-induced plasma free fatty acid decrease in man Diabetologia 1966, 2:127-129
22. Carlson LA, Freyschuss U, Kjellberg J, Ostman J Suppression of splanchnic ketone body production in man by nicotinic acid Diabetologia 1967, 3:494-499
23. Carlson LA, Levi L, Oro L Plasma lipids and urinary excretion of catecholamines in man during experimentally induced emotional stress, and their modification by nicotinic acid J Clin Invest 1968, 47:1795-1805
24. Lassers BW, Wahlqvist ML, Kaijser L, Carlson LA Effect of nicotinic acid on myocardial metabolism in man at rest and during exercise J Appl Physiol 1972, 33:72-80
25. Carlson LA Serum lipids in men with myocardial infarction Acta Med Scand 1960, 167:399-413
26. Castelli W Epidemiology of triglycerides: A view from Framingham Am J Cardiol 1992, 70:3H-9H
27. Gordon T, Castelli WP, Hjortland MC, et al High-density lipoprotein as a protective factor against coronary heart disease The Framingham Study Am J Med 1977, 62:707-714
28. Miller GJ, Miller NE Plasma high-density lipoprotein concentration and development of ischaemic heart disease Lancet 1975, I:16-19
29. Beaumont JL, Carlson LA, Cooper GR, et al Classification of hyperlipidemias and hyperlipoproteinemias Bull World Health Organization 1970, 43:891-915
30. Fredrickson DA, Levy RI, Lees RS Fat transport in lipoproteins: an integrated approach to mechanisms and disorders N Engl J Med 1967, 276:34-44 94-103, 148-156, 215-225, 273-281
31. Havel RJ, Eder HA, Bragdon JH The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J Clin Invest 1955, 34:1345-1353
32. Johansson JO, Egberg N, Asplund-Carlson A, et al Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men J Cardiovasc Risk 1997, 4:165-171
33. Carlson LA, Oro L Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia Atherosclerosis 1973, 18:1-9
34. Carlson LA, Hamsten A, Asplund A Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid J Intern Med 1989, 226:271-276
35. Lithell H, Vessby B, Walldius G, Carlson LA Hypertriglyceridemia, acute pancreatitis and ischemic heart disease in a pair of monozygotic twins Acta Med Scand 1987, 221:311-316
36. Carlson LA, Danielson M, Eckberg I, et al Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid Atherosclerosis 1977, 28:81-86
37. Carlson LA, Rosenhamer G Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid Acta Med Scand 1988, 223:405-418
38. Whitney EJ, Krasuski RA, Personius BE, et al A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events Ann Intern Med 2005, 142:95-104
39. The Coronary Drug Project Research Group The Coronary Drug Project Design, methods, and baseline results Circulation 1973, 47(Suppl I):I1-I50
40. The Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease JAMA 1975, 231:360-381
41. The Coronary Drug Project Research Group The Coronary Drug Project: Initial findings leading to modifications of its research protocol JAMA 1970, 214:1303-1313
42. The Coronary Drug Project Research Group The Coronary Drug Project: findings leading to further modifications of its protocol with respect to dextrothyroxine JAMA 1972, 220:996-1008
43. The Coronary Drug Project Research Group The Coronary Drug Project: findings leading to discontinuation of the 25 mg/day estrogen group JAMA 1973, 226:652-657
44. Cox DR Regression models and life-tables J R Statist Soc B 1972, 34:187-202
45. Canner PL, Berge KG, Wenger NK, for the Coronary Drug Project Research Group, et al fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 1986, 81:1245-1255
46. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 2002, 106:3143-3421
47. Garg A, Grundy SM Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus J Am Med Assoc 1990, 264:723-726
48. Canner PL, Furberg CD, Terrin ML, McGovern ME Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project) Am J Cardiol 2005, 95:254-257
49. Canner PL, Furberg CD, McGovern ME Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project) Am J Cardiol 2006, 97:477-479
50. Language SAS Reference 2002, SAS Institute, Inc, Cary, NC, 82 version 1st ed
51. Blankenhorn DH, Nessim SA, Johnson RL, et al Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts JAMA 1987, 257:3233-3240
52. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al Beneficial effects of colestipol-niacin on coronary atherosclerosis A 4-year follow-up JAMA 1990, 264:3013-3017
53. Hodis HN, Mack WJ Triglyceride-rich lipoproteins and progression of atherosclerosis Eur Heart J 1998, 19(Suppl A):A40-A44
54. Kane JP, Malloy MJ, Ports TA, et al Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens JAMA 1990, 264:3007-3012
55. Brown BG, Hillger LA, Lewis C, et al A maximum confidence approach for measuring progression and regression of coronary artery disease in clinical trials Circulation 1993, 87(Suppl II):II66-II73
56. Brown G, Albers JJ, Fisher LD, et al Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 1990, 323:1289-1298
57. Zhao XQ, Brown BG, Hillger L, et al Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B Circulation 1993, 88:2744-2753
58. Assman G, Schulte H, von Eckardstein A, et al High-density lipoprotein cholesterol as a predictor of coronary heart disease risk The PROCAM experience and pathophysiological implications for reverse cholesterol transport Atherosclerosis 1996, 124(Suppl):S11-S20
59. Gordon DJ, Probstfield JL, Garrison LJ, et al High-density lipoprotein cholesterol and cardiovascular disease Four prospective American studies Circulation 1989, 79:8-15
60. Brown BG, Zhao XQ, Sacco DE, Albers JJ Lipid lowering and plaque regression New insights into prevention of plaque disruption and clinical events in coronary disease Circulation 1993, 87:1781-1791
61. Maher VM, Brown BG, Marcovina SM, et al Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a) JAMA 1995, 274:1771-1774
62. Haskell WL, Alderman EL, Fair JM, et al Effects of intensive multiple risk factor reduction on coronary atherosclerosis and cardiac events in men and women with coronary artery disease The Stanford Coronary Risk Intervention Project (SCRIP) Circulation 1994, 89:975-990
63. Quinn TG, Alderman EL, McMillan A, et al Development of new coronary atherosclerotic lesions during a 4-year multiple risk factor reduction program: the Stanford Coronary Risk Intervention Project (SCRIP) J Am Coll Cardiol 1994, 24:900-908
64. Miller BD, Alderman EL, Haskell WL, et al Predominance of dense low-density lipoprotein particles predicts angiographic benefit or therapy in the Stanford Coronary Risk Intervention Project Circulation 1996, 94:2146-2153
65. Sacks FM, Pasternac RC, Gibson CM, et al Effects on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients Lancet 1994, 344:1182-1186
66. Brown BG, Brockenbrough A, Zhao XQ, et al Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow up Circulation 1998, 98(Suppl 1):I-635
67. Zhao XQ, Yuan C, Hatsukami TS, et al Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study Arterioscler Thromb Vasc Biol 2001, 21(10):1623-1629
68. Davies MJ, Richardson PD, Woolf N, et al Risk of thrombosis in human atherosclerotic plaques Role of extracellular lipid, macrophages, and smooth muscle cell content Brit Heart J 1993, 69:377-381
69. Brown BG, Zhao XQ, Chait A, et al Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 2001, 345:1583-1592
70. Taylor AJ, Sullenberger LE, Lee HJ, et al Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2 A double-blind, placebo-controlled study of extended release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 2004, 110:3512-3517
71. Taylor AJ, Lee HJ, Sullenberger LE The effect of 24 months of combination statin and extended release niacin on carotid intima-media thickness ARBITER 3 Curr Med Res Opin 2006, 22:2243-2250
72. Brown BG, Stukovsky KH, Zhao XQ Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials Curr Opin Lipidol 2006, 17:631-636
73. Brown BG, Zhao XQ, Cheung MC Should both HDL cholesterol and LDL cholesterol be targets for lipid therapy? A review of current evidence J Clin Lipidology 2007, 1:88-94
74. Guyton JR Extended-release niacin for modifying the lipoprotein profile Expert Opin Pharmacother 2004, 5:1385-1398
75. Piepho RW The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol Am J Cardiol 2000, 86(Suppl):35L-40L
76. Knopp RH, Ginsberg J, Albers JJ, et al Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin Metabolism 1985, 34:642-650
77. McKenney JM, Proctor JD, Harris S, Chinchili VM A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients J Am Med Assoc 1994, 271:672-677
78. Cefali EA, Adams MH Extended-release niacin pharmacokinetics following multiple-dose administration Pharmacotherapy 2003, 23:125
79. Cefali EA Effect of over-the-counter sustained-release niacin on serum transaminases Pharmacotherapy 2003, 23:126
80. McCormack PL, Keating GM Prolonged-release nicotinic acid A review of its use in the treatment of dyslipidaemia Drugs 2005, 65:2719-2740
81. McGovern M Niaspan: Creating a new concept for raising HDL cholesterol Eur Heart J 2005, 7(Suppl F):F41-F47
82. Sprecher DL Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review Am J Cardiol 2000, 86(Suppl):46L-50L
83. Stroes ES, Birjmohum RS, Hutten BA, Kastelein JJ Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials J Am Coll Cardiol 2005, 45:185-197
84. Myers CD, Carr MC, Park S, Brunzell JD Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia Ann Inter Med 2003, 139:996-1002
85. Mosca L, Appel LJ, Benjamin EJ, et al American Heart Association: evidence-based guidelines for cardiovascular disease prevention in women Circulation 2004, 109:672-692
86. Levy DR, Pearson TA Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease Clin Cardiol 2005, 28:317-320
87. Hunninghake DB, McGovern ME, Koren M, et al A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin Clin Cardiol 2003, 26:112-118
88. Kashyap ML, McGovern ME, Berra K, et al Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia Am J Cardiol 2002, 89:672-678
89. Ballantyne CM, Davidson MH, McKenney J, et al Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I Study) Am J Cardiol 2008, 101:1428-1436
90. Ballantyne CM, Davidson MH, McKenney JM, et al Comparison of thet efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study J Clin Lipidol 2008, 2:79-90
91. Guyton JR, Goldberg AC, Kreisberg RA, et al Effectiveness of once nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia Am J Cardiol 1998, 82:737-743
92. Zhao XQ, Morse JS, Dowdy AA, et al Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study) Am J Cardiol 2004, 93:307-312
93. Kelly JJ, Lawson JA, Campbell LV, et al Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects J Hum Hypertens 2000, 14:567-572
94. Rasouli N, Hale T, Kahn SE, et al Effects of short-term experimental insulin resistance and family history of diabetes on pancreatic beta-cell function in nondiabetic individuals J Clin Endocrinol Metab 2005, 90:5825-5833
95. Poynten AM, Gan SK, Kriketos AD, et al Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content Metabolism 2003, 52:699-704
96. Vega GL, Cater NB, Meguro S, et al Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia Am J Cardiol 2005, 95:1309-1313
97. Elam MB, Hunninghake DB, Davis KE, et al Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease The ADMIT study: A randomized trial JAMA 2000, 284:1263-1270
98. Grundy SM, Vega GL, McGovern ME, et al Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes Arch Intern Med 2002, 162:1568-1576
99. Christensen NA, Achor RWP, Berge KG, et al Nicotinic acid treatment of hypercholesterolemia J Am Med Assoc 1961, 177:76-80
100. Henkin Y, Johnson KC, Segrest JP Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin J Am Med Assoc 1990, 264:241-243
101. Capuzzi DM, Guyton JR, Morgan JM, et al Efficacy and safety of an extended-release niacin (Niaspan): A long-term study Am J Cardiol 1999, 82:74U-81U
102. Gharavi AG, Diamond JA, Smith DA, et al Niacin-induced myopathy Am J Cardiol 1994, 74:841-842
103. Litin SC, Anderson CF Nicotinic acid-associated myopathy: A report of three cases Am J Med 1989, 86:481-483
104. Cooke HM Lovastatin- and niacin-induced rhabdomyolysis Hosp Pharm 1994, 29:33-34
105. Norman DJ, Illingworth DR, Munson J, et al Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin [letter] N Engl J Med 1988, 318:46-47
106. Reaven P, Witztum JL Lovastatin, nicotinic acid, and rhabdomyolysis Ann Intern Med 1988, 109:597-598
107. Duvall WL, Blazing MA, Saxena S, et al Targeting cardiovascular risk associated with both low-density and high-density lipoprotein using statin-niacin combination therapy J Cardiovasc Risk 2002, 9:339-347
108. Advicor Prescribing Information Abbott Laboratories, North Chicago, IL August 2007
109. Rubenfire M Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study Am J Cardiol 2004, 94:306-311
110. Sheikh-Ali AA, Karas RH Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system) Am J Cardiol 2007, 99:379-381
111. Guyton JR, Bays HE Safety considerations with niacin therapy Am J Cardiol 2007, 99(Suppl C):22C-31C
112. Fraunfelder FW, Fraunfelder FT, Illingworth DR Adverse ocular effects associated with niacin therapy Brit J Opthalmol 1995, 79:54-56
113. Bressler NM Cystoid macular edema from niacin typically is not accompanied by fluorescein leakage on angiography Am J Ophthalmol 2005, 139:951
114. Gass JD Nicotinic acid maculopathy Am J Ophthalmol 1973, 76:500-510
115. Mosher LR Nicotinic acid side effects and toxicity: A review Am J Psychiatry 1970, 126:1290-1296
116. Gershon SL, Fox IH Pharmacologic effects of nicotinic acid on human purine metabolism J Lab Clin Med 1974, 84:179-186
117. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomized placebo-controlled trial Lancet 2002, 360:7-22
118. LaRosa JC, He J, Vupputuri S Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials JAMA 1999, 282:2340-2346
119. Brown BG, Zambon A, Lanman RB, et al Frequency and importance of conversion to large buoyant LDL with simvastatin and niacin therapy: Comparison of four methods Circulation 2003, 108(Suppl IV):IV-197
120. Clark RW, Sutfin TA, Ruggeri RB, et al Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib Arterioscler Thromb Vasc Biol 2004, 24:490-497
121. Knopp RH, Alagona P, Davidson M, et al Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia Metabolism 1998, 47:1097-1104
122. Cefali EA, Simmons PD, Stanek EJ, Shamp TR Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation Int J Clin Pharmacol Ther 2006, 44:633-640
123. Cefali EA, Simmons PD, Stanek EJ Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation Int J Clin Pharmacol Ther 2007, 45:78-88
124. Benyo Z, Gille A, Bennett CL, et al Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells Mol Pharmacol 2006, 70:1844-1849
125. Lorenzen A, Stannek C, Lang H, et al Characterization of a G protein-coupled receptor for nicotinic acid Mol Pharmacol 2001, 59:349-357
126. Jin FY, Kamanna VS, Kashyap ML Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells Arterioscler Thromb Vasc Biol 1999, 19:1051-1059
127. Jin FY, Kamanna VS, Kashyap ML Niacin decreases the removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by HepG2 cells Implications for reverse cholesterol transport Arterioscler Thromb Vasc Biol 1997, 17:2020-2028
128. Rubic T, Trottman M, Lorenz RL Stimulation of CD 36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin Biochem Pharmacol 2004, 67:411-419
129. Paolini JF, Mitchel YB, Reyes R, et al Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia Am J Cardiol 2008, 101:625-630
130. Lai E, De Lepeleire I, Crumley TM, et al Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1 Clin Pharmacol Ther 2007, 81:849-857
131. Xydakis AM, Ballantyne CM Combination therapy for combined dyslipidemia AM J Cardiol 2002, 90(Suppl):21K-29K